|
|
|
| Clinical Efficacy of Chinese Medicine Combined with Paclitaxel and Carboplatin in the Treatment of Ovarian Cancer |
| TAN Chang-an, WU Jin-hua, LI Xiao-li |
| Department of Obstetrics and Gynecology, Xi'an XD Group Hospital, Xi'an Shaanxi, 710077 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical effect of traditional Chinese medicine (TCM) Yiqi-Huoxue (invigorating qi and activating blood circulation) combined with paclitaxel and carbohydrates in the treatment of ovarian cancer and the changes of related factors. 【Methods】 A total of 82 patients with ovarian cancer treated in our hospital from May 2016 to February 2019 were randomly divided into two groups with 41 cases in each. The control group was treated with paclitaxel combined with carboplatin, and the observation group was treated with traditional Chinese medicine Yiqi-Huoxue for invigorating qi and activating blood circulation on the basis of the control group. The clinical effect of the two groups after treatment was analyzed. 【Results】 The overall effective rate in the observation group (73.17%) was higher than that in the control group (51.22%), and the difference was statistically significant (P<0.05). There was no significant difference in tumor markers and cellular immune indexes between the two groups before treatment (P>0.05). After treatment, the levels of IL-2 (IL-2) and interferon-gamma (INF- γ) in the observation group were higher than those in the control group (P<0.05), and the levels of carbohydrate antigen (CA199), carbohydrate antigen (CA125), human epididymal protein 4 (HE4) and IL-10 (IL-10) were lower than those in the control group (P<0.05). There was no significant difference in TCM syndrome score and Karst (KPS) score between the two groups before treatment (P>0.05). After treatment, the score of KPS in the observation group (79.69±6.14) was higher than that in the control group (68.59±5.20), and the score of TCM syndromes (13.02±2.89) in the observation group was lower than that in the control group (17.98±3.28; P<0.05). 【Conclusion】 Traditional Chinese medicine for invigorating qi and activating blood circulation combined with paclitaxel can improve the cellular immune level, decrease the expression level of tumor markers and improve the quality of life in patients with ovarian cancer.
|
|
Received: 18 October 2019
|
|
|
|
|
|
[1] 马纪荣.恩度联合紫杉醇和卡铂方案治疗晚期卵巢癌的临床疗效和安全性研究[J].天津药学,2017,29(1):46-48.
[2] 张富斌,崔李宁,徐科君.紫杉醇脂质体与传统紫杉醇联合卡铂治疗卵巢癌的疗效及不良反应的对比分析[J].中华全科医学,2017,15(5):808-810.
[3] 张振华,李怡帆,卢委平.中医治疗晚期妇科恶性肿瘤验案三则[J].国际中医中药杂志,2017,39(2):115-117.
[4] 潘金丽.益气健脾养血汤联合多西紫杉醇与顺铂治疗晚期卵巢癌[J].中医学报,2018,33(7):1186-1189.
[5] 周琦,吴小华,刘继红,等.卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749.
[6] 郑筱萸.中药新药临床研究指导原则(试用)[M].北京:中国医药科技出版社,2002:135.
[7] 杨学宁, 吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,2(2):25-30.
[8] 游捷,施志明.肺癌国际生存质量量表与体能状态评定指标及中医症状量表的关系[J].中国中西医结合杂志,2005,25(7):595-599.
[9] 王静,万靓,李威.紫杉醇联合卡铂治疗卵巢癌的效果分析[J].实用临床医药杂志,2018,22(1):80-83.
[10] 卢琪芸,张慧雅,张宜群.临床初步评估紫杉醇脂质体结合卡铂在卵巢癌治疗中的效果[J].中国性科学,2017,26(6):29-31.
[11] 散琴,刘洋,段玉平,等.血清HE4、SMRP、CA125、CA199、B7-H4、TPS联合检测紫杉醇联合卡铂化疗对卵巢癌患者的效果[J].海南医学院学报,2017,23(14):1980-1982.
[12] 袁慧,郭翠琴,武芳.益气活血解毒散结法对晚期卵巢癌患者无复发生存时间、生活质量及免疫功能的影响[J].现代中西医结合杂志,2019,28(8):883-886.
[13] 贾锋.自拟中药方剂联合常规西医化疗治疗晚期卵巢癌的效果分析[J].海峡药学,2017,29(2):169-171.
[14] 黄相艳.桂枝茯苓丸加减配合西药治疗晚期卵巢癌患者临床疗效[J].陕西中医,2017,38(5):643-645.
[15] 杨慧,徐叶芳,李富娟,等.PLR、HE4及CA125在卵巢癌患者中的表达及其意义[J].医学临床研究,2019,36(12):2467-2468.
[16] 刘红梅,刘世专.贝伐单抗联合紫杉醇、卡铂方案治疗复发性卵巢癌的效果和安全性[J].中国当代医药,2017,24(19):91-93.
[17] 周能芳.免疫细胞治疗联合化疗治疗晚期卵巢癌患者的疗效及对细胞免疫的影响[J].现代肿瘤医学,2018,26(3):436-440. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(6): 1143-1144. |
|
|
|
|
2020, Vol. 37 
